MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.760
-0.020
-0.53%
After Hours: 3.770 +0.01 +0.27% 19:34 08/11 EDT
OPEN
3.790
PREV CLOSE
3.780
HIGH
3.793
LOW
3.670
VOLUME
312.04K
TURNOVER
--
52 WEEK HIGH
5.15
52 WEEK LOW
1.850
MARKET CAP
342.11M
P/E (TTM)
-6.0160
1D
5D
1M
3M
1Y
5Y
1D
Guggenheim Remains a Buy on SAB Biotherapeutics (SABS)
TipRanks · 2d ago
Weekly Report: what happened at SABS last week (0803-0807)?
Weekly Report · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Genmab (GMAB), Sotera Health (SHC)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)
TipRanks · 5d ago
SAB Biotherapeutics reports Q2 results
Seeking Alpha · 6d ago
*SAB Biotherapeutics 2Q Loss $22.5M >SABS
Dow Jones · 6d ago
*SAB Biotherapeutics: Operational Runway Through 2028 to Support SAFEGUARD Study, PRISE-hATG Study and pre-Comml Activities >SABS
Dow Jones · 6d ago
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Dow Jones · 6d ago
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.